Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7032204 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7029868 | 0.86 | ITGB3 (0.69) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7025929 | 0.86 | ITGB3 (0.62) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7025715 | 0.83 | ITGB3 (0.88) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7035528 | 0.83 | ITGB3 (0.67) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7116507 | 0.81 | ITGB3 (0.50) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7030491 | 0.80 | ITGB3 (0.57) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7032202 | 0.79 | ITGB3 (0.74) | ITGB3ITGA2B | |
| SCHEMBL7344920 | 0.77 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7343076 | 0.72 | ITGB3 (0.82) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135045-A1 | Glycoprotein IIb/IIIa antagonists | FISHER MATTHEW J (US) | 2003-07-17 | — | — | US | disclosed |
| EP-0635492-B1 | Glycoprotein IIb/IIIa antagonists | LILLY CO ELI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6137002-A | USEFUL FOR PREVENTION OF THROMBOSIS; FOR TREATING ATHEROSCLEROSIS AND ARTERIOSCLEROSIS, ACUTE MYOCARDIAL INFARCTION, CHRONIC STABLE ANGINA, UNSTABLE ANGINA, TRANSIENT ISCHEMIC ATTACKS AND STROKES, PERIPHERAL VASCULAR DISEASE, | ELI LILLY AND COMPANY (US) | 2000-10-24 | — | — | US | disclosed |
| US-5618843-A | INHIBIT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0635492-A1 | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135045-A1 | Glycoprotein IIb/IIIa antagonists | GP6, TBXA2R, ITGA2B | ITGB3 14/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.